Eli Lilly’s GLP-1 Dominance: Positioning for Multi-Decade Wealth Creation in the Obesity Revolution
Eli Lilly has seized leadership in the GLP-1 market with tirzepatide-based Mounjaro and Zepbound, driving explosive revenue growth and capturing over 60% U.S. market share. Recent results show combined tirzepatide sales exceeding $36 billion in 2025, with Q4 alone topping $11 billion amid triple-digit gains. The company guides $80-83 billion in 2026 revenue, fueled by … Read more